FDA announces warning on unapproved thyroid pills — then guarantees to ‘ensure access’ to them
The recent declaration from the Food and Drug Administration (FDA) concerning non-approved thyroid treatments has led to a complicated and sometimes inconsistent scenario for both patients and medical professionals. The agency has issued a significant alert about the potential safety hazards linked to these medications, particularly a type of "animal-derived thyroid" (ADT) products. At the same time, the FDA has expressed its plan to "maintain accessibility" to these exact medications, at least for a temporary phase. This dual communication highlights the fragile equilibrium the FDA must maintain between its duty to safeguard public health and its obligation to avoid disrupting…







